Table 2.
Baseline serum biomarker levels stratified by long-term response to vedolizumab. Values are displayed as medians with IQR.
| Biomarker | Continued Use n = 17 |
Discontinued Use n = 15 |
p-Value |
|---|---|---|---|
| C1M (ng/mL) | 36.1 [25.02–49.80] | 108.6 [57.47–148.45] | 0.001 |
| C3M (ng/mL) | 10.5 [9.43–11.81] | 15.2 [13.07–16.44] | 0.006 |
| PRO-C3 (ng/mL) | 6.4 [4.43–8.40] | 5.7 [5.34–6.49] | 0.610 |
| C3M/PRO-C3 | 1.6 [1.42–1.80] | 2.6 [1.98–3.13] | 0.008 |
| C4M (ng/mL) | 24.5 [22.36–28.16] | 36.5 [28.24–46.68] | 0.010 |
| C4G (ng/mL) | 19.4 [15.19–30.24] | 18.0 [13.56–26.74] | 0.558 |
| PRO-C4 (ng/mL) | 182.0 [170.48–203.68] | 266.8 [207.20–308.26] | 0.010 |
| C4M/C4G | 1.4 [0.81–1.77] | 2.0 [1.40–2.44] | 0.020 |
| PRO-C4/C4M | 7.2 [6.10–8.06] | 6.9 [6.51–7.75] | 0.925 |
| PRO-C4/C4G | 8.4 [6.02–12.56] | 14.5 [9.66–17.12] | 0.033 |
| C6Ma3 (ng/mL) | 0.6 [0.53–0.84] | 0.8 [0.68–1.02] | 0.015 |
| CPa9-HNE (ng/mL) | 231.7 [195.32–302.60] | 401.2 [281.36–452.00] | 0.003 |
| CPa9-HNE/C4G | 11.6 [6.46–16.43] | 18.5 [11.14–29.28] | 0.052 |